21-063 - Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLLStatus: open
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Treatment for Lymphocytic Leukemia/Small Lymphocytic Lymphoma
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at email@example.com.
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
Providers Associated With This Trial
- Omar Alkharabsheh, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology; Associate Program Director, Medical Oncology Fellowship
- Brian E. Persing, M.D.Medical Oncologist and HematologistDivision Director, Medical Oncology; Arlene and Mayer Mitchell Chair of Medical Oncology; Program Director, Medical Oncology Fellowship; Assistant Professor of Medical Oncology